Rankings / Longevity — Supplements
ER-100 (partial epigenetic reprogramming)
Longevity · Partial epigenetic reprogramming
Tier D
Bottom line
Read Off Label grades ER-100 (partial epigenetic reprogramming) as D (2.9/10) based on preclinical evidence, high benefit magnitude, and a high-risk safety profile.
Life Biosciences (co-founded by David Sinclair).
Typical use: Intravitreal AAV-OSK plus 8-week oral doxycycline activation (NAION/glaucoma trial) — Investigational.
What this is
Life Biosciences (co-founded by David Sinclair). First partial-reprogramming therapy dosed in a human: FDA cleared the IND Jan 2026 and the first Phase 1 patient was dosed Jun 9 2026 — believed to be the world's first in-human test of partial epigenetic reprogramming. Phase 1 (NCT07290244) in non-arteritic anterior ischemic optic neuropathy (NAION) and open-angle glaucoma; safety/tolerability primary, with visual-function endpoints; $80M Series D Apr 2026. No published human efficacy yet. Distinct from the preclinical Yamanaka-factor class row. Frontier — the field's most ambitious longevity modality. Company-sponsored.
Mechanism
AAV-delivered OSK (Oct4/Sox2/Klf4) Yamanaka factors, transiently activated by oral doxycycline, reset age-associated epigenetic marks in retinal cells without dedifferentiation, aiming to restore youthful function rather than slow damage.
Dose & route
Intravitreal AAV-OSK plus 8-week oral doxycycline activation (NAION/glaucoma trial)
Citations
- https://clinicaltrials.gov/study/NCT07290244
- https://www.lifebiosciences.com/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies/
- https://www.lifebiosciences.com/life-biosciences-announces-fda-clearance-of-ind-application-for-er-100-in-optic-neuropathies/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does ER-100 (partial epigenetic reprogramming) work?
- Read Off Label rates the evidence for ER-100 (partial epigenetic reprogramming) as Preclinical and the benefit magnitude as high, producing an overall grade of D (2.9/10). Life Biosciences (co-founded by David Sinclair).
- Is ER-100 (partial epigenetic reprogramming) safe?
- ER-100 (partial epigenetic reprogramming) has a high risk profile in published human data. Legal status: Investigational (Phase 1; first patient dosed Jun 9 2026). This is not medical advice — see the disclaimer.
- What is the typical dose for ER-100 (partial epigenetic reprogramming)?
- Intravitreal AAV-OSK plus 8-week oral doxycycline activation (NAION/glaucoma trial)
- How does ER-100 (partial epigenetic reprogramming) work?
- AAV-delivered OSK (Oct4/Sox2/Klf4) Yamanaka factors, transiently activated by oral doxycycline, reset age-associated epigenetic marks in retinal cells without dedifferentiation, aiming to restore youthful function rather than slow damage.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.